Michelle Fanale

Michelle Fanale

UNVERIFIED PROFILE

Are you Michelle Fanale?   Register this Author

Register author
Michelle Fanale

Michelle Fanale

Publications by authors named "Michelle Fanale"

Are you Michelle Fanale?   Register this Author

100Publications

4412Reads

13Profile Views

CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab era.

Leuk Lymphoma 2019 Sep 18:1-9. Epub 2019 Sep 18.

Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center , Houston , TX , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1663418DOI Listing
September 2019

Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival ?

Ann Hematol 2019 May 8;98(5):1169-1176. Epub 2019 Jan 8.

Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, WA, Australia.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00277-018-3571-7
Publisher Site
http://dx.doi.org/10.1007/s00277-018-3571-7DOI Listing
May 2019

Stage I Non-Hodgkin Lymphoma: difference in survival outcome by primary extranodal site of involvement.

Br J Haematol 2019 Apr 5;185(2):334-338. Epub 2018 Jul 5.

Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15444DOI Listing
April 2019

Outcome of patients with relapsed or refractory anaplastic large cell lymphoma who have failed brentuximab vedotin.

Hematol Oncol 2019 Feb 23;37(1):35-38. Epub 2018 Oct 23.

Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/hon.2560
Publisher Site
http://dx.doi.org/10.1002/hon.2560DOI Listing
February 2019

Post-ABVD biopsy results, and not post-ABVD FDG-PET results, predict outcome in early-stage Hodgkin lymphoma: response to Adams and Kwee.

Br J Haematol 2019 01 19;184(2):292-293. Epub 2017 Dec 19.

Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15072DOI Listing
January 2019

Radiotherapy in Patients with Mycosis Fungoides and Central Nervous System Involvement.

Case Rep Oncol 2018 Sep-Dec;11(3):721-728. Epub 2018 Nov 12.

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000494081DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276745PMC
November 2018

Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma.

J Clin Oncol 2018 10 4;36(30):3015-3022. Epub 2018 Sep 4.

Andrew M. Evens, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; Ranjana H. Advani, Stanford University, Stanford, CA; Irene B. Helenowski, Borko D. Jovanovic, Jane N. Winter, and Leo I. Gordon, Northwestern University Feinberg School of Medicine; Jane N. Winter and Leo I. Gordon, Robert H. Lurie Comprehensive Cancer Center; Sonali M. Smith, University of Chicago, Chicago, IL; Michelle Fanale, University of Texas MD Anderson Cancer Center, Houston, TX; Gregory R. Bociek, University of Nebraska, Omaha, NE; Andreas K. Klein, Tufts Medical Center, Boston, MA; and Paul A. Hamlin, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.79.0139DOI Listing
October 2018

Prevalence of a Histologic Change of Ocular Adnexal Lymphoma in Patients With a History of Lymphoma.

Ophthalmic Plast Reconstr Surg 2018 Aug 17. Epub 2018 Aug 17.

Orbital Oncology and Ophthalmic Plastic Surgery, Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, U.S.A.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/IOP.0000000000001215DOI Listing
August 2018

Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.

J Clin Oncol 2018 05 27;36(14):1428-1439. Epub 2018 Mar 27.

Philippe Armand and Margaret A. Shipp, Dana-Farber Cancer Institute, Boston, MA; Andreas Engert, University Hospital of Cologne, Cologne, Germany; Anas Younes, Memorial Sloan Kettering Cancer Center, New York, NY; Michelle Fanale, University of Texas MD Anderson Cancer Center, Houston, TX; Armando Santoro, Humanitas Cancer Center, Humanitas University, Milan; Pier Luigi Zinzani, Institute of Hematology "L. e A. Seràgnoli," University of Bologna, Bologna, Italy; John M. Timmerman, University of California Los Angeles Medical Center, Los Angeles, CA; Graham P. Collins, Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford, United Kingdom; Radhakrishnan Ramchandren, Barbara Ann Karmanos Cancer Institute, Detroit, MI; Jonathon B. Cohen, Winship Cancer Institute, Emory University, Atlanta, GA; Jan Paul De Boer, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands, on behalf of Lunenburg Lymphoma Phase I/II Consortium; John Kuruvilla, University of Toronto and Princess Margaret Cancer Centre, Toronto, Ontario; Kerry J. Savage, BC Cancer Agency, Vancouver, British Columbia, Canada; Marek Trneny, Charles University, General Hospital in Prague, Prague, Czech Republic; Kazunobu Kato, Anne Sumbul, and Benedetto Farsaci, Bristol-Myers Squibb, Princeton, NJ; and Stephen M. Ansell, Mayo Clinic, Rochester, MN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.0793DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6075855PMC
May 2018

Beyond Chemotherapy: Checkpoint Inhibition and Cell-Based Therapy in Non-Hodgkin Lymphoma.

Am Soc Clin Oncol Educ Book 2018 May;38:592-603

From the Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX; Children's National Health System and The George Washington University, Washington, DC; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX; Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_200549DOI Listing
May 2018

Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.

J Clin Oncol 2018 04 2;36(10):942-950. Epub 2018 Feb 2.

Margaretha G.M. Roemer, Robert A. Redd, Fathima Zumla Cader, Christine J. Pak, Sara Abdelrahman, Jing Ouyang, Philippe Armand, Donna S. Neuberg, and Margaret A. Shipp, Dana-Farber Cancer Institute; Geraldine S. Pinkus, Azra H. Ligon, and Scott J. Rodig, Brigham and Women's Hospital, Boston, MA; Margaretha G.M. Roemer, VU University Medical Center; Jan Paul De Boer, Antoni van Leeuwenhoek Hospital, Lunenburg Phase I/II Consortium, Amsterdam, the Netherlands; Stephanie Sasse, University Hospital of Cologne, Cologne, Germany; Anas Younes, Memorial Sloan Kettering Cancer Center, New York, NY; Michelle Fanale, University of Texas MD Anderson Cancer Center, Houston, TX; Armando Santoro, Humanitas University, Rozzano, Milan; Pier Luigi Zinzani, University of Bologna, Bologna, Italy; John Timmerman, University of California, Los Angeles Medical Center, Los Angeles, CA; Graham P. Collins, Churchill Hospital, Oxford, United Kingdom; Radhakrishnan Ramchandren, Barbara Ann Karmanos Cancer Institute, Detroit, MI; Jonathon B. Cohen, Emory University, Atlanta, GA; John Kuruvilla, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Kerry J. Savage, British Columbia Cancer Agency Center for Lymphoid Cancer, Vancouver, British Columbia, Canada; Marek Trneny, Charles University in Prague, General University Hospital in Prague, Prague, Czech Republic; Stephen Ansell, Mayo Clinic, Rochester, MN; and Kazunobu Kato, Benedetto Farsaci, and Anne Sumbul, Bristol-Myers Squibb, Princeton, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.77.3994DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877802PMC
April 2018

Phase I Dose-Escalation Study of Anti-CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers.

Mol Cancer Ther 2018 03 13;17(3):671-676. Epub 2017 Dec 13.

Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-17-0673DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5935561PMC
March 2018

SOHO State of the Art Updates and Next Questions: Hodgkin Lymphoma.

Clin Lymphoma Myeloma Leuk 2018 02 4;18(2):81-90. Epub 2018 Jan 4.

Washington University School of Medicine, St. Louis, MO. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2018.01.001DOI Listing
February 2018

Dose-Adjusted EPOCH-R and Mid-Cycle High Dose Methotrexate for Patients with Systemic Lymphoma and secondary CNS Involvement.

Br J Haematol 2017 12 9;179(5):851-854. Epub 2016 Aug 9.

Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14267DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6063086PMC
December 2017

Brentuximab vedotin for advanced Hodgkin's lymphoma.

Lancet Oncol 2017 12 10;18(12):1566-1568. Epub 2017 Nov 10.

Department of Lymphoma and Myeloma, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(17)30845-8DOI Listing
December 2017

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.

J Clin Oncol 2017 Jul 25;35(19):2125-2132. Epub 2017 Apr 25.

Robert Chen, City of Hope National Medical Center, Duarte, CA; Pier Luigi Zinzani, University of Bologna, Bologna, Italy; Michelle A. Fanale, The University of Texas MD Anderson Cancer Center, Houston, TX; Philippe Armand and Margaret A. Shipp, Dana-Farber Cancer Institute, Boston, MA; Nathalie A. Johnson, Jewish General Hospital, Montreal, Canada; Pauline Brice, Hôpital Saint-Louis, Paris; Vincent Ribrag, Institut Gustave Roussy, Villejuif, France; John Radford, The University of Manchester and Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom; Daniel Molin, Uppsala University, Uppsala, Sweden; Theodoros P. Vassilakopoulos, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece; Akihiro Tomita, Nagoya University Graduate School of Medicine, Nagoya, Japan; Bastian von Tresckow, University Hospital Cologne, Cologne, Germany; Yinghua Zhang, Alejandro D. Ricart, and Arun Balakumaran, Merck, Kenilworth, NJ; Craig H. Moskowitz, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.72.1316DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791843PMC
July 2017

The Management of Lymphoma in the Setting of Pregnancy.

Curr Hematol Malig Rep 2017 06;12(3):251-256

Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-017-0386-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5650107PMC
June 2017

Lymphoma and Pregnancy-Reply.

JAMA Oncol 2017 04;3(4):567-568

Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2016.4848DOI Listing
April 2017

Management of Anaplastic Large Cell Lymphoma.

Hematol Oncol Clin North Am 2017 04;31(2):209-222

Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard Unit 429, Houston, TX 77030, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2016.11.001DOI Listing
April 2017

Does Bleomycin Lung Toxicity Increase the Risk of Radiation Pneumonitis in Hodgkin Lymphoma?

Int J Radiat Oncol Biol Phys 2016 12 22;96(5):951-958. Epub 2016 Aug 22.

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2016.08.018DOI Listing
December 2016

Nodular lymphocyte-predominant Hodgkin lymphoma.

Semin Hematol 2016 Jul 13;53(3):190-202. Epub 2016 May 13.

MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminhematol.2016.05.009DOI Listing
July 2016

US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.

J Clin Oncol 2016 06 11;34(17):2020-7. Epub 2016 Apr 11.

Oliver W. Press, Fred Hutchinson Cancer Research Center, and the University of Washington; Hongli Li and Michael LeBlanc, Fred Hutchinson Cancer Research Center, Seattle, WA; Heiko Schöder, David J. Straus, Craig H. Moskowitz, and Ariela Noy, Memorial Sloan Kettering Cancer Center; John P. Leonard, Weill Cornell Medical College and New York Presbyterian Hospital, New York City; Paul M. Barr and Jonathan W. Friedberg, University of Rochester Medical Center, Rochester, NY; Lisa M. Rimsza, University of Arizona, Tucson, AZ; Nancy L. Bartlett and Brad S. Kahl, Washington University School of Medicine, St. Louis, MO; Andrew M. Evens, Tufts Medical Center; Ann S. LaCasce, Dana-Farber Cancer Institute, Boston, MA; Erik S. Mittra, Stanford University Medical Center, Stanford, CA; John W. Sweetenham, Huntsman Cancer Hospital, Salt Lake City, UT; Michelle A. Fanale, University of Texas MD Anderson Cancer Center, Houston, TX; Michael V. Knopp, The Ohio State University, Columbus; Eric D. Hsi, Cleveland Clinic Foundation; James R. Cook, Cleveland Clinic, Cleveland, OH; Mary Jo Lechowicz, Winship Cancer Institute of Emory University, Atlanta, GA; Randy D. Gascoyne, British Columbia Cancer Agency, Vancouver, BC; Bruce D. Cheson, Georgetown University Hospital, Washington DC; and Richard I. Fisher, Fox Chase Cancer Center, Philadelphia, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.63.1119DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966513PMC
June 2016

Prognostic Factors of Hepatosplenic T-cell Lymphoma: Clinicopathologic Study of 28 Cases.

Am J Surg Pathol 2016 May;40(5):676-88

Departments of *Hematopathology †Stem Cell Transplantation §Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX #Biostatistics **Translational and Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston ¶Department of Pathology, UT Southwestern Medical Center, Dallas, TX ‡Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY ∥Department of Pathology, University of Miami, Miami, FL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAS.0000000000000614DOI Listing
May 2016

Deeper Insights Into Vanishing Bile Duct Syndrome in Lymphoma: A Perplexing Entity.

Clin Lymphoma Myeloma Leuk 2016 05 27;16(5):e65-70. Epub 2016 Feb 27.

Division of Cancer Medicine, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2016.02.035DOI Listing
May 2016

New insights into NLPHL transformation.

Authors:
Michelle Fanale

Blood 2016 Apr;127(16):1946-7

THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2016-03-699108DOI Listing
April 2016

Patient-reported outcomes of brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma.

Onco Targets Ther 2016 6;9:2027-34. Epub 2016 Apr 6.

Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S96175DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4827881PMC
April 2016

Novel treatments for T-cell lymphoma.

Am Soc Clin Oncol Educ Book 2015 :e468-78

From the Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14694/EdBook_AM.2015.35.e468DOI Listing
February 2016

Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant-Associated Anaplastic Large-Cell Lymphoma.

J Clin Oncol 2016 Jan 30;34(2):160-8. Epub 2015 Nov 30.

Mark W. Clemens, L. Jeffrey Medeiros, Charles E. Butler, Kelly K. Hunt, Michelle A. Fanale, Jun Liu, Rashmi Kanagal-Shamanna, Jing Ning, Summer E. Hanson, Loretta J. Nastoupil, Yasuhiro Oki, Ken H. Young, and Roberto N. Miranda, The University of Texas MD Anderson Cancer Center, Houston, TX; Steven Horwitz, Neha Mehta-Shah, Ahmed Dogan, and Colleen M. McCarthy, Memorial Sloan Kettering Cancer Center, New York, NY; Dennis D. Weisenburger, City of Hope National Medical Center, Duarte, CA; Elizabeth A. Morgan, Brigham and Women's Hospital and Harvard Medical School; Aliyah R. Sohani and Judith A. Ferry, Massachusetts General Hospital and Harvard Medical School, Boston, MA; Vinita Parkash, Yale School of Medicine, New Haven, CT; Hui Liu, Xuzhou Medical College, Xuzhou, People's Republic of China; Nora Thormann, Fundacao Universitaria Mario Martins, Porto Alegre, Brazil; Arianna DiNapoli, Sant'Andrea Hospital, Sapienza University, Rome, Italy; Stephen Lade, University of Melbourne, Melbourne, Victoria, Australia; Jorge Piccolini, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; Ruben Reyes, Kansas University Medical Center, Kansas City, KS; Travis Williams, St Luke's Mountain States Tumor Institute, Meridian, ID; and Rakesh Gaur, St Luke's Hospital, Kansas City, MO.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.63.3412DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872006PMC
January 2016

Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma.

Br J Haematol 2015 Nov 27;171(4):463-70. Epub 2015 Jul 27.

Department of Lymphoma/Myeloma, The University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.13603DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5278973PMC
November 2015

Outcomes After Chemotherapy Followed by Radiation for Stage IIB Hodgkin Lymphoma With Bulky Disease.

Clin Lymphoma Myeloma Leuk 2015 Nov 5;15(11):664-670.e2. Epub 2015 Aug 5.

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2015.07.633DOI Listing
November 2015

Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study.

Lancet Haematol 2015 Apr 25;2(4):e166-74. Epub 2015 Mar 25.

Department of Haematology, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Melbourne, VIC, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3026(15)00026-5DOI Listing
April 2015

Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study.

J Clin Oncol 2014 Oct 18;32(28):3137-43. Epub 2014 Aug 18.

Michelle A. Fanale, The University of Texas MD Anderson Cancer Center, Houston, TX; Steven M. Horwitz, Memorial Sloan-Kettering Cancer Center, New York, NY; Andres Forero-Torres, University of Alabama at Birmingham, Birmingham, AL; Nancy L. Bartlett, Washington University School of Medicine, St Louis, MO; Ranjana H. Advani, Stanford University Medical Center, Palo Alto; Robert W. Chen, City of Hope National Medical Center, Duarte, CA; Barbara Pro, Fox Chase Cancer Center, Philadelphia, PA; Dirk Huebner, Takeda Pharmaceuticals International, Cambridge, MA; Dana A. Kennedy, Seattle Genetics, Bothell; Andrei R. Shustov, University of Washington Medical Center, Seattle, WA; Andrew Davies, University of Southampton School of Medicine, Southampton; Tim Illidge, Institute of Cancer Sciences, University of Manchester, Manchester, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.54.2456DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4171358PMC
October 2014

Breast implant-associated anaplastic large cell lymphoma: sensitivity, specificity, and findings of imaging studies in 44 patients.

Breast Cancer Res Treat 2014 Aug 30;147(1):1-14. Epub 2014 Jul 30.

Department of Diagnostic Radiology Unit 1350, The University of Texas, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-014-3034-3DOI Listing
August 2014